SS1 (Roche) / June 18^th 11:30~12:20

Yeul Hong Kim, MD, Ph D. Division of Medical Oncology Director of Korea University Anam Hospital Cancer Center "A decade of anti-angiogenic therapy: past, present and future"

SS2(MSD) / June 18^th 11:30~12:20

Kenneth O'Byrne, MD Professor, Consultant Medical Oncologist Princess Alexandra Hospital Queensland University of Technology, Australia "Emerging role of immunotherapy"

SS3(Novartis) / June 18^th 18:00~19:00   

Dong Wan Kim, M.D., Ph.D. Department of Internal Medicine, Seoul National University Hospital Seoul National University College of Medicine, Seoul Korea "New Treatment in ALK+ Lung Cancer"

SS4 (Bayer) / June 18^th 18:00~20:00

Salvatore Siena, M.D., Ph.D. Director, Dipartimento di Ematologia e Oncologia, Ospedale Niguarda Ca' Granda, Milan, Italy "Colorectal Cancer The role of targeted therapies in the strategy of mCRC treatement"

Do-Youn Oh, M.D., Ph.D. Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea "Revisit of antiangiogenesis strategy in gastric cancer"

Dirk Laurent Bayer (Global Drug Development) "How to address new targets in oncology"

Sun Young Rha, M.D., Ph.D. Yonsei Cancer Center, Yonsei University College of Medicine "Research experience for biomarker development in GI cancer"

SS5 (ONO Pharma and BMS) / June 19^th 12:00~12:50  

Jonathan Simon Cebon, MBBS, PhD, FRACP Professor of Medicine at the University of Melbourne and a Fellow of the Royal Australasian College of Physicians, Australia "Immunology translational research and Immune check point inhibitors in solid tumors"

SS6 (Lilly) / June 19^th 12:00~12:50

Se-Hoon Park, M.D., Ph.D. Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University Samsung Medical Center, Seoul, Korea "Emerging Standard-Of-Care in Second-Line gastric cancer"